Condition: Non-small Cell Lung Cancer · Sponsor: Xin-Hua Xu
The aim of evaluating the efficacy and safety of cadonilimab combined with monotherapy chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) with negative driver genes who have failed previous immunotherapy is to provide a more effective and safe treatment option for these patients.
This description comes directly from the study's public registry record.
Xinhua Xu, Master · +8613986747496 · 2732774352@qq.com
Xinhua Xinhua, Master · +8613986747496 · 2732774352@qq.com
Always discuss trial participation with your own doctor first.
| Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University | Yichang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06467500